[go: up one dir, main page]

BR9607851B1 - combinaÇço e formulaÇço farmacÊutica. - Google Patents

combinaÇço e formulaÇço farmacÊutica.

Info

Publication number
BR9607851B1
BR9607851B1 BRPI9607851-0A BR9607851A BR9607851B1 BR 9607851 B1 BR9607851 B1 BR 9607851B1 BR 9607851 A BR9607851 A BR 9607851A BR 9607851 B1 BR9607851 B1 BR 9607851B1
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
BRPI9607851-0A
Other languages
English (en)
Other versions
BR9607851A (pt
Inventor
David Walter Barry
Clair Martha Heider St
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9607851(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed filed Critical
Publication of BR9607851A publication Critical patent/BR9607851A/pt
Publication of BR9607851B1 publication Critical patent/BR9607851B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
BRPI9607851-0A 1995-03-30 1996-03-28 combinaÇço e formulaÇço farmacÊutica. BR9607851B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
BR9607851A BR9607851A (pt) 1998-07-21
BR9607851B1 true BR9607851B1 (pt) 2009-01-13

Family

ID=26306774

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI9612992-1A BRPI9612992B1 (pt) 1995-03-30 1996-03-28 Combinação, e, formulação farmacêutica
BRPI9607851A BRPI9607851B8 (pt) 1995-03-30 1996-03-28 combinação e formulação farmacêutica.
BRPI9607851-0A BR9607851B1 (pt) 1995-03-30 1996-03-28 combinaÇço e formulaÇço farmacÊutica.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI9612992-1A BRPI9612992B1 (pt) 1995-03-30 1996-03-28 Combinação, e, formulação farmacêutica
BRPI9607851A BRPI9607851B8 (pt) 1995-03-30 1996-03-28 combinação e formulação farmacêutica.

Country Status (35)

Country Link
US (1) US6417191B1 (pt)
EP (1) EP0817637B1 (pt)
JP (1) JP2954357B2 (pt)
KR (1) KR100542536B1 (pt)
CN (1) CN1103593C (pt)
AP (1) AP652A (pt)
AT (1) ATE220551T1 (pt)
AU (1) AU715213B2 (pt)
BR (3) BRPI9612992B1 (pt)
CA (1) CA2216634C (pt)
CZ (1) CZ295940B6 (pt)
DE (3) DE122005000029I2 (pt)
DK (1) DK0817637T3 (pt)
EA (1) EA000626B3 (pt)
EE (1) EE04047B1 (pt)
ES (1) ES2179193T3 (pt)
FR (1) FR05C0022I2 (pt)
GE (1) GEP20022647B (pt)
HU (1) HU224010B1 (pt)
IL (1) IL117727A (pt)
LU (1) LU91171I2 (pt)
MX (1) MX9707316A (pt)
MY (1) MY115461A (pt)
NL (1) NL300195I2 (pt)
NO (2) NO313787B1 (pt)
NZ (1) NZ306419A (pt)
OA (1) OA10616A (pt)
PL (1) PL187085B1 (pt)
PT (1) PT817637E (pt)
RO (1) RO117995B1 (pt)
SI (1) SI0817637T1 (pt)
SK (1) SK283825B6 (pt)
TR (1) TR199701074T1 (pt)
UA (1) UA60293C2 (pt)
WO (1) WO1996030025A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU7912398A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
CA2518823A1 (en) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
WO2005040816A1 (en) 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
DK2120878T3 (da) * 2007-02-09 2014-11-03 Alphapharm Pty Ltd Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CN115348864A (zh) 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DE69206876T3 (de) 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
HU224010B1 (hu) 2005-04-28
DE69622386T2 (de) 2003-02-13
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
IL117727A0 (en) 1996-07-23
AP652A (en) 1998-06-19
DE69622386D1 (de) 2002-08-22
HK1009401A1 (en) 1999-09-10
KR100542536B1 (ko) 2006-03-23
NO313787B1 (no) 2002-12-02
IL117727A (en) 1999-11-30
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
MX9707316A (es) 1997-11-29
LU91171I2 (fr) 2005-07-04
MY115461A (en) 2003-06-30
ATE220551T1 (de) 2002-08-15
NO2005014I2 (no) 2008-02-11
CN1185110A (zh) 1998-06-17
EA199700203A1 (ru) 1998-02-26
KR19980703420A (ko) 1998-11-05
AU715213B2 (en) 2000-01-20
JP2954357B2 (ja) 1999-09-27
US6417191B1 (en) 2002-07-09
PL187085B1 (pl) 2004-05-31
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
LU91171I9 (pt) 2018-12-28
BRPI9612992B1 (pt) 2020-08-04
AU5497296A (en) 1996-10-16
DK0817637T3 (da) 2002-11-11
CZ309097A3 (cs) 1998-05-13
BRPI9607851B8 (pt) 2019-11-05
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
EP0817637A1 (en) 1998-01-14
CN1103593C (zh) 2003-03-26
EA000626B1 (ru) 1999-12-29
EP0817637B1 (en) 2002-07-17
CA2216634C (en) 2004-07-20
PL322532A1 (en) 1998-02-02
EA000626B3 (ru) 2016-04-29
NO974510L (no) 1997-09-29
FR05C0022I2 (pt) 2005-10-21
DE122005000029I2 (de) 2006-04-27
NL300195I2 (nl) 2005-11-01
UA60293C2 (uk) 2003-10-15
NO974510D0 (no) 1997-09-29
OA10616A (en) 2001-03-15
HUP9801571A2 (hu) 1999-01-28
CZ295940B6 (cs) 2005-12-14
DE122005000029I1 (de) 2005-10-06
ES2179193T3 (es) 2003-01-16
SI0817637T1 (en) 2002-10-31
FR05C0022I1 (pt) 2005-06-10
CA2216634A1 (en) 1996-10-03
NO2005014I1 (no) 2005-06-06
BR9607851A (pt) 1998-07-21
SK129597A3 (en) 1998-07-08
JPH10511682A (ja) 1998-11-10
HUP9801571A3 (en) 2001-04-28
EE04047B1 (et) 2003-06-16
RO117995B1 (ro) 2002-12-30
EE9700240A (et) 1998-04-15

Similar Documents

Publication Publication Date Title
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
BR9611367A (pt) Formulação farmacêutic liofilizada estável
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FI973243A0 (fi) Uusi farmaseuttinen yhdistelmä
DE69525148D1 (de) Pharmazeutische formulierung
ID24654A (id) Formulasi farmasi omeprazola
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
NO981008D0 (no) Farmasöytisk formulering
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
NO20021172D0 (no) Farmasöytisk sammensetning
ATE187063T1 (de) Arzneimittel
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
BR9509688A (pt) Composto e composição farmacêutica
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
DZ1926A1 (fr) Formulations pharmaceutiques.
ATE258010T1 (de) Pestizide formulierung
LV11727A (lv) Farmaceitiska kompozicija
FI973280L (fi) Farmaseuttinen koostumus
FI973230L (fi) Uusi farmaseuttinen formulaatio
BR9606066A (pt) Composto e formulação farmacêutica
NL1007839A1 (nl) Formulering en gebruik.
BR9605777A (pt) Composição farmacêutica

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/02/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061560/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132356-33.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: THE SECRETARY OF STATE FOR DEFENCE, THE WELLCOME FOUNDATION LIMITED, THERATECHNOLOGIES INC, UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY, UNIVERSITE DE MONTREAL.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061560/2013-54 SECAO JUDICIARIA DO RIO DE JANEIRO 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0132356-33.2013.4.02.5101APELADO: THE SECRETARY OF STATE FOR DEFENCE E OUTROS APELANTE: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: PELO EXPOSTO, DIVIRJO DO EXMO. RELATOR E DOU PROVIMENTO AO RECURSO DE APELACAO E JULGO PROCEDENTE O PEDIDO ALTERNATIVO, PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9508392-8, PI 9607850-2, PI 9607851-0, PI 9608799-4, PI 9607752-2 E PI 9510423-2, E DETERMINAR A CORRECAO DE SEUS RESPECTIVOS PRAZOS DE VIGENCIA CONFORME TABELA A SEGUIR:PATENTE: PI 9508392-8 NOVO PRAZO DE VIGENCIA: 12/07/2015PATENTE: PI 9607850-2 NOVO PRAZO DE VIGENCIA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/02/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A PUBLICACAO NA RPI 1990 DE 25.02.2009, QUANTO AO PRAZO DE VIGENCIA: ATE 28.03.2016, CONFORME DECISAO JUDICIAL PUBLICADA NA RPI 2547 DE 29.10.2019 - INPI 52400.061560/2013